Solara Active Pharma Sciences Limited has issued a revised intimation regarding its upcoming conference call with analysts and investors to discuss Q3FY26 financial results. The pharmaceutical company filed the updated notification with BSE and NSE on February 03, 2026, announcing a change in the timing of the previously scheduled earnings call.

Revised Conference Call Details

The company has updated the earnings call schedule with the following revised specifications:

Key Management Participation

The earnings call will feature senior management representatives who will discuss the company's performance:

• Arun Kumar - Founder & Non-Executive Director
• Sandeep Rao - Managing Director & CEO
• Sarat Kumar - Chief Financial Officer

Financial Results Coverage

The conference call will cover Solara Active Pharma Sciences' unaudited financial results for the quarter and nine months ended December 31, 2025. This represents the company's Q3FY26 performance, providing insights into the pharmaceutical company's operational and financial metrics during this period.

Access Information

The company has provided multiple access options for participants:

The revised intimation was signed by Pooja Jaya Kumar, Company Secretary & Compliance Officer (Membership No: A57415), and filed under Regulation 30 compliance requirements with both BSE (Scrip Code: 541540, 890202) and NSE (Symbol: SOLARA, SOLARAPPI). All other details from the original intimation dated January 30, 2026, remain unchanged except for the timing modification.

Solara Active Pharma Sciences Limited , a prominent player in the pharmaceutical industry, continues to strengthen its employee incentive programs through strategic stock option allotments. The company's Board of Directors recently approved another allotment under the Solara Employee Stock Option Plan 2018.

Latest ESOP Allotment Details

On December 17, 2025, the Board of Directors approved the allotment of 1,500 equity shares under the employee stock option plan. The key details of this latest allotment are:

Updated Share Capital Structure

The allotment has resulted in changes to the company's share capital structure:

The newly allotted shares rank pari-passu with existing equity shares in all respects.

Previous ESOP Activities

This follows the company's earlier allotment of 8,040 equity shares in November 2025, which raised Rs. 30.15 lakhs. The company had also previously granted 25,000 stock options to employees with an exercise price of Rs. 375.00 per share and a structured vesting schedule over three years.

Financial Performance Context

The diluted earnings per share remains at Rs. 19.00 following this allotment. These employee stock option exercises are part of Solara's broader strategy to align employee interests with shareholder value while the company works on improving its financial performance and exploring strategic restructuring opportunities including the potential demerger of its CRAMS and Polymers business.

Regulatory Compliance

The allotment complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The options were exercised within the prescribed 120-day period from the vesting date.